Health and Healthcare
Clovis Looks to Cash in on Secondary Offering
Published:
Last Updated:
Shares of Clovis Oncology Inc. (NASDAQ: CLVS) saw a handy gain in Wednesday’s session after the company priced its secondary offering. This offering comes on the heels of a massive gain that the stock made at the beginning of the week. It’s no doubt that the firm is looking to cash in on this incredible rise and make a few extra bucks.
The stock closed last week at roughly $60 per share, and since then it has climbed over 55% to the current price level above $90.
Clovis is offering roughly 3.41 million shares for $88 per share, with an overallotment option for an additional 511,363 shares. The size of the offering was upsized to $300 million from $250 million.
The underwriters for the offering are JPMorgan, Merrill Lynch, Stifel and SunTrust Robinson Humphrey.
The company intends to use the net proceeds of the offering for general corporate purposes, including sales and marketing expenses associated with Rubraca (rucaparib) in the United States and, if approved by the European Medicines Agency (EMA), in Europe; funding of its development programs; general and administrative expenses; acquisition or licensing of additional product candidates or businesses; and working capital.
Since the stock jumped, a few analysts have weighed in on Clovis:
Shares of Clovis were last seen up nearly 6% at $93.80 on Wednesday, with a consensus analyst price target of $90.91 and a 52-week range of $11.57 to $93.97.
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.